LLY

1,030.06

+0.68%↑

JNJ

243.75

+1.91%↑

ABBV

224.33

+1.19%↑

NVS

160.78

+0.8%↑

MRK

120.94

+2.06%↑

LLY

1,030.06

+0.68%↑

JNJ

243.75

+1.91%↑

ABBV

224.33

+1.19%↑

NVS

160.78

+0.8%↑

MRK

120.94

+2.06%↑

LLY

1,030.06

+0.68%↑

JNJ

243.75

+1.91%↑

ABBV

224.33

+1.19%↑

NVS

160.78

+0.8%↑

MRK

120.94

+2.06%↑

LLY

1,030.06

+0.68%↑

JNJ

243.75

+1.91%↑

ABBV

224.33

+1.19%↑

NVS

160.78

+0.8%↑

MRK

120.94

+2.06%↑

LLY

1,030.06

+0.68%↑

JNJ

243.75

+1.91%↑

ABBV

224.33

+1.19%↑

NVS

160.78

+0.8%↑

MRK

120.94

+2.06%↑

Search

AtriCure Inc

Atvērts

SektorsVeselības aprūpe

31.84 -1.36

Pārskats

Akcijas cenas izmaiņa

24h

Šī brīža

Min

31.03

Max

33.38

Galvenie mērījumi

By Trading Economics

Ienākumi

5.9M

-267K

Pārdošana

-1.9M

134M

Peļņas marža

-0.199

Darbinieki

1,300

EBITDA

7.3M

8M

Rekomendācijas

By TipRanks

Rekomendācijas

Pirkt (spēcīgs)

Prognoze 12 mēnešiem

+34.89% upside

Dividendes

By Dow Jones

Nākamie ieņēmumi

2026. g. 17. febr.

Tirgus statistika

By TradingEconomics

Tirgus kapitalizācija

-30M

1.8B

Iepriekšējā atvēršanas cena

33.2

Iepriekšējā slēgšanas cena

31.84

Ziņu noskaņojums

By Acuity

71%

29%

319 / 352 Rangs Healthcare

Tehniskais rādītājs

By Trading Central

Pārliecība

Strong Bearish Evidence

AtriCure Inc Grafiks

Pagātnes rezultāti nav uzticams nākotnes rezultātu rādītājs.

Saistītās ziņas

2026. g. 11. febr. 23:47 UTC

Karstas akcijas

Stocks to Watch: AppLovin, Cisco, Cognex, Pilgrim's Pride

2026. g. 11. febr. 22:59 UTC

Peļņas
Iegādes, apvienošanās, pārņemšana

Grab Holdings to Buy U.S.-Based Stash Financial

2026. g. 11. febr. 23:54 UTC

Peļņas

McDonald's Says Its Value Campaign Is Paying Off -- 2nd Update

2026. g. 11. febr. 23:50 UTC

Tirgus saruna

Global Equities Roundup: Market Talk

2026. g. 11. febr. 23:50 UTC

Tirgus saruna

Nikkei May Rise on Hopes for Takaichi's Economic Steps -- Market Talk

2026. g. 11. febr. 23:49 UTC

Peļņas

Singtel: Key Focus Areas Are Strengthening Core Businesses, Scaling Growth Engines, Building Momentum Across Regional Associates >Z74.SG

2026. g. 11. febr. 23:45 UTC

Peļņas

Singtel: Net Exceptional Gain of S$1.15B in 3Q Primarily From Sale of Partial Stake in Bharti Airtel>Z74.SG

2026. g. 11. febr. 23:42 UTC

Peļņas

Singtel 3Q Underlying Net Profit S$744M Vs. S$680M >Z74.SG

2026. g. 11. febr. 23:41 UTC

Peļņas

Singtel 3Q Net S$1.89B Vs. Net S$1.32B >Z74.SG

2026. g. 11. febr. 23:40 UTC

Peļņas

Singtel 3Q Operating Revenue S$3.66B Vs. S$3.63B >Z74.SG

2026. g. 11. febr. 23:35 UTC

Tirgus saruna

Gold Falls on Prospects of Long Fed Pause -- Market Talk

2026. g. 11. febr. 23:18 UTC

Tirgus saruna

AppLovin CEO Looks to Soothe Concerns Over AI, Competition -- Market Talk

2026. g. 11. febr. 23:14 UTC

Tirgus saruna

RBA Governor Faces Barrage of Questions About Govt Spending -- Market Talk

2026. g. 11. febr. 22:59 UTC

Peļņas

Kakao 2025 Net KRW525.72B Vs. Loss KRW161.87B >035720.SE

2026. g. 11. febr. 22:59 UTC

Peļņas

Kakao 2025 Oper Pft KRW732.04B Vs. Pft KRW460.21B >035720.SE

2026. g. 11. febr. 22:59 UTC

Peļņas

Kakao 2025 Rev KRW8.099T Vs. KRW7.872T >035720.SE

2026. g. 11. febr. 22:58 UTC

Peļņas

Kakao 4Q Net Loss Missed FactSet-Compiled Consensus

2026. g. 11. febr. 22:57 UTC

Peļņas

Kakao 4Q Loss KRW39.30B Vs. Loss KRW395.21B >035720.SE

2026. g. 11. febr. 22:54 UTC

Peļņas

Kakao 4Q Oper Pft KRW203.45B Vs. Pft KRW75.43B >035720.SE

2026. g. 11. febr. 22:53 UTC

Peļņas

Kakao 4Q Rev KRW2.133T Vs. KRW1.957T >035720.SE

2026. g. 11. febr. 22:47 UTC

Peļņas

AppLovin Reports Strong Earnings. The Stock Is Down. -- Barrons.com

2026. g. 11. febr. 22:47 UTC

Peļņas

AppLovin Reports Strong Earnings. The Stock Is Down. -- Barrons.com

2026. g. 11. febr. 22:23 UTC

Peļņas

Grab Holdings Expects to Close Stash Acquisition in 3Q of 2026 >GRAB

2026. g. 11. febr. 22:22 UTC

Peļņas

Grab Holdings to Acquire U.S. Digital Financial Services Company Stash Financial >GRAB

2026. g. 11. febr. 22:22 UTC

Peļņas

Grab Holdings Sees FY26 Adj Ebitda $700M to $720M >GRAB

2026. g. 11. febr. 22:19 UTC

Peļņas

Grab Holdings Sees FY26 Rev $4.04B to $4.10B >GRAB

2026. g. 11. febr. 22:18 UTC

Peļņas

Grab Holdings 4Q Adj Ebitda $148.0M Vs. $97.0M >GRAB

2026. g. 11. febr. 22:18 UTC

Peļņas

Grab Holdings 4Q Net $153.0M Vs. Net $11.0M >GRAB

2026. g. 11. febr. 22:18 UTC

Peļņas

Grab Holdings 4Q Oper Pft $52.0M Vs. $2.0M >GRAB

2026. g. 11. febr. 22:16 UTC

Peļņas

Grab Holdings 4Q Rev $906.0M Vs. $764.0M >GRAB

Salīdzinājums

Cenas izmaiņa

AtriCure Inc Prognoze

Cenas mērķis

By TipRanks

34.89% augšup

Prognoze 12 mēnešiem

Vidējais 49.8 USD  34.89%

Augstākais 64 USD

Zemākais 36 USD

Pamatojoties uz 5 Volstrītas analītiķiem, kuri piedāvā 12 mēnešu cenu mērķi AtriCure Inc — pēdējo 3 mēnešu laikā.

Vērtējuma vienprātība

By TipRanks

Pirkt (spēcīgs)

5 ratings

4

Pirkt

1

Turēt

0

Pārdot

Tehniskais rādītājs

By Trading Central

30.36 / 33.4Atbalsts un pretestība

Īstermiņā

Strong Bearish Evidence

Vidējā termiņā

Strong Bearish Evidence

Ilgtermiņā

Strong Bearish Evidence

Noskaņojums

By Acuity

319 / 352 Rangs Veselības aprūpe

Ziņu noskaņojums

Liecība "Lāču" tendencei

Volatilitāte

Zem vidējā

Ziņu apjoms (RCV)

Virs vidējā

Finanšu rādītāji

Pārdošanas un administrēšanas izmaksas

Darbības izmaksas

Peļņa pirms nodokļu nomaksas

Pārdošana

Pārdošanas maksa

Bruto peļņa no pārdošanas

Procentu izdevumi par parādu

EBITDA

Pamatdarbības peļņa

$

Par AtriCure Inc

AtriCure, Inc. develops, manufactures, and sells devices for surgical ablation of cardiac tissue, exclusion of the left atrial appendage, and temporarily blocking pain by ablating peripheral nerves to medical centers in the United States, Europe, the Asia-Pacific, and internationally. The company offers Isolator Synergy Clamps, single-use disposable radio frequency products; multifunctional pens and linear ablation devices, such as the MAX Pen device that enables surgeons to evaluate cardiac arrhythmias, perform temporary cardiac pacing, sensing, and stimulation, and ablate cardiac tissue with the same device; and the Coolrail device, which enables users to make longer linear lines of ablation. It also provides cryoICE Cryoablation System that enables the user to make linear ablations of varied lengths; EPi-Sense Systems, a single-use disposable device used for the treatment of symptomatic, drug-refractory, and long-standing persistent atrial fibrillation; cryoSPHERE probe, which provides temporary pain relief by applying cryothermic energy to targeted intercoastal peripheral nerves in the ribcage; AtriClip System, an implantable device coupled to a single-use disposable applier; and LARIAT System, a suture-based solution for soft-tissue closure. In addition, the company sells Lumitip dissectors to separate tissues to provide access to key anatomical structures that are targeted for ablation; Glidepath guides for placement of clamps; Subtle Cannula's to support access for EPi-Sense catheters; and various reusable cardiac surgery instruments. It markets and sells its products through independent distributors and direct sales personnel. The company was incorporated in 2000 and is headquartered in Mason, Ohio.
help-icon Live chat